TLX News: IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate - 16th Apr 2025, 8:45am

[annb0t]

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study[2].(PRNewsfoto/Telix Pharmaceuticals Limited)

IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety...

>>> Read more: IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate